Quick answer
Newborns have no validated definition of acute kidney injury, so clinicians have used the adult serum creatinine threshold — which is misleading in the first days of life, when creatinine still reflects the mother's kidneys and muscle mass. A team at Nanfang Hospital led by Hou Fanfan showed that serum cystatin C detects neonatal AKI far better, and KDIGO's 2026 AKI guideline has adopted their standard [1][2][4].
Key takeaways
- The KDIGO 2026 AKI/AKD guideline, released 10 June 2026, adopted the cystatin C-based neonatal AKI definition [1][3].
- The evidence came from 52,000 newborns in the China Kidney Disease Big Data Collaborative Network, published in JASN in 2023 [2].
- Sensitivity was 5.5 times higher than creatinine-based diagnosis [4].
- The threshold: cystatin C ≥2.2 mg/L, or a rise of ≥25% from baseline within seven days [4].
- It is the fourth international guideline the team has changed, following RASi in advanced CKD, the ROAD dosing strategy and mycophenolate for IgA nephropathy [5].
The problem
Acute kidney injury is common in critically ill newborns and worsens outcomes, but diagnosis has been borrowed from adults. In the first week of life, creatinine is influenced by maternal levels and by the baby's muscle mass, so a "normal" value can hide injury; conversely, a value that looks abnormal may be normal for age [1][2].
Cystatin C is produced steadily by all nucleated cells and cleared by the kidney, so it is less dependent on muscle mass and less affected by maternal transfer. The Nanfang team tested it at scale, using a national collaborative network to assemble 52,000 neonatal records and derive thresholds that separate injury from normal variation [2][3].
What changed in the guideline
KDIGO is the body whose definitions most countries follow. Its 2026 guideline replaces the adult creatinine threshold for neonates with the cystatin C criteria, which means neonatal units worldwide now have a validated definition to diagnose and stage AKI — and a basis for enrolling newborns in trials [1][3]. For a neonatal unit, the practical change is one extra blood test alongside the sepsis workup that most sick newborns already receive [4].
Better diagnosis does not by itself improve outcomes; it enables earlier recognition and research. Cystatin C assays are not universally available in neonatal units, and thresholds derived in Chinese newborns need validation in other populations. The guideline adoption is a significant step, but implementation will be uneven [2][3].
The condition in context: neonatal AKI
AKI in newborns is under-recognised and associated with longer stays and higher mortality.
| Region | What the data shows | Source |
|---|---|---|
| Diagnosis | No neonatal-specific standard existed before; adult creatinine criteria were applied [1]. | Nanfang Daily [1] |
| Missed cases | Creatinine-based diagnosis has serious error in newborns, causing substantial under-diagnosis [2]. | SMU / Nanfang [2] |
| Scale of evidence | 52,000 newborns were analysed to derive the new thresholds [2]. | SMU [2] |
Because neonatal AKI is often reversible if recognised early, a definition that detects it sooner has direct clinical value [1].
Why it matters
| Potential | What the report suggests | Source |
|---|---|---|
| Sensitivity | 5.5-fold better detection than creatinine [4]. | [4] |
| Standardisation | A single definition enables trials and benchmarking [1]. | [1] |
| Caution | Assay availability and external validation remain issues [2]. | [2] |
Availability and limits
- This is an editorial summary of guideline and hospital reports, not clinical advice [1][2].
- Cystatin C testing may not be routine in all neonatal units [3].
- Thresholds were derived in Chinese newborns [2].
- A definition does not guarantee better treatment or outcomes [1].
- The team's earlier guideline changes are separate achievements, not evidence for this one [5].
What to ask before booking
| Question | Why it matters |
|---|---|
| Is cystatin C measured in my baby's unit? | The new definition depends on it [4]. |
| How is AKI staged and managed here? | Early recognition should trigger fluid and drug review [1]. |
| Which department handles foreign patients, and in what language? | Nanfang Hospital is a working hospital we do not book; confirm international-department coordination and language support. |
| What follow-up is planned for kidney function? | Neonatal AKI carries later risk of chronic kidney disease [2]. |
Questions patients ask
What changed?
KDIGO's 2026 AKI guideline adopted a neonatal AKI definition based on serum cystatin C, developed by Nanfang Hospital's team [1][3].
Why is creatinine inadequate in newborns?
Early values reflect maternal creatinine and the baby's muscle mass, causing both false positives and missed injury [1][2].
What are the new thresholds?
Cystatin C ≥2.2 mg/L, or a rise of ≥25% from baseline within seven days [4].
How strong was the evidence?
A study of 52,000 newborns published in JASN in 2023, showing 5.5-fold higher sensitivity than creatinine [2][4].
Is this relevant to international patients?
It is useful context for China's nephrology research. Nanfang Hospital is a working hospital we do not book — contact its international department directly [1].